NCT00573755View on ClinicalTrials.gov

Sorafenib and Letrozole, Anastrozole, or Exemestane in Treating Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Metastatic Breast Cancer

PHASE2TerminatedINTERVENTIONAL

Enrollment

4

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

April 30, 2013

Study Completion Date

April 30, 2013

Conditions

Breast Cancer

Interventions

DRUG

anastrozole

given orally

DRUG

exemestane

given orally

DRUG

letrozole

given orally

DRUG

sorafenib tosylate

given orally

OTHER

placebo

given orally

Trial Locations (3)

32224

Mayo Clinic in Florida, Jacksonville

55259

Mayo Clinic in Arizona, Scottsdale

55905

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Mayo Clinic

OTHER